Liproxstatin-1: Potent Ferroptosis Inhibitor with Benchmark IC50 22 nM

Executive Summary: Liproxstatin-1 is a potent, selective small molecule inhibitor of ferroptosis, with an IC50 of approximately 22 nM in cell-based assays (APExBIO). It blocks lipid peroxidation and provides robust cytoprotection, especially in GPX4-deficient models (Yu et al., 2025). Liproxstatin-1 has demonstrated efficacy in vivo, including protection against renal failure and hepatic ischemia/reperfusion injury. The compound is insoluble in water but highly soluble in DMSO and ethanol with proper handling. Its reproducible activity and well-characterized mechanism position Liproxstatin-1 as a reference tool for ferroptosis research and translational studies.

Biological Rationale

Ferroptosis is a regulated form of cell death dependent on iron and characterized by the accumulation of lipid peroxides. This death pathway is distinct from apoptosis, necrosis, and cuproptosis, and is relevant in contexts such as organ injury, neurodegeneration, and cancer therapy (Yu et al., 2025). Ferroptosis is triggered when the glutathione peroxidase 4 (GPX4) pathway is compromised, allowing unchecked lipid peroxidation. Small-molecule modulators like Liproxstatin-1 are essential for dissecting the roles of ferroptosis in both physiological and disease states. APExBIO provides Liproxstatin-1 (B4987), a benchmark tool for this purpose (APExBIO).

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 acts by selectively inhibiting ferroptosis through the blockade of lipid peroxide accumulation. It prevents the formation and propagation of phospholipid hydroperoxides, especially under conditions where GPX4 is deficient or inactivated. Liproxstatin-1 does not interfere with other forms of cell death, such as apoptosis or cuproptosis. Instead, it specifically intercepts the lipid peroxidation pathway, halting the cascade that leads to membrane damage and cell death (Yu et al., 2025). The specificity of Liproxstatin-1 has been validated in both cellular and animal models, using inducers such as RSL3 to trigger ferroptosis (APExBIO).

Evidence & Benchmarks

• Liproxstatin-1 inhibits ferroptosis with an IC50 of ~22 nM in cell-based assays using GPX4-deficient models (APExBIO).
• It effectively blocks lipid peroxidation induced by RSL3, a GPX4 inhibitor, in vitro (Yu et al., 2025).
• In conditional kidney-specific Gpx4 knockout mice, Liproxstatin-1 administration prolongs survival and reduces renal tissue damage (Yu et al., 2025).
• Liproxstatin-1 reduces hepatic injury and tissue damage in rodent models of ischemia/reperfusion (Yu et al., 2025).
• The compound is insoluble in water but soluble at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol (with warming/ultrasound), facilitating use in experimental workflows (APExBIO).

For a broader context on ferroptosis, see Liproxstatin-1 and the Next Frontier in Ferroptosis Research, which surveys plasma membrane dynamics—this article extends mechanistic detail and translational benchmarks.

Additionally, Liproxstatin-1: Strategic Deployment of a Potent Ferroptosis Inhibitor provides a roadmap for advanced disease modeling; here, we focus on physicochemical workflow and benchmarking parameters.

Applications, Limits & Misconceptions

Liproxstatin-1 is central to workflows investigating the iron-dependent cell death pathway and the lipid peroxidation cascade. It is used in:

• Cellular models of GPX4 deficiency and oxidative stress.
• Animal models of acute kidney injury, hepatic ischemia/reperfusion, and emerging cancer paradigms.
• Studies of ferroptosis modulation in drug discovery and mechanistic biology.

Common Pitfalls or Misconceptions

• Liproxstatin-1 does not block cell death pathways unrelated to ferroptosis (e.g., apoptosis, pyroptosis, or cuproptosis).
• Water insolubility requires pre-dissolution in DMSO/ethanol; direct aqueous use leads to precipitation and loss of activity.
• Not effective if lipid peroxidation is not the driver of cell death; inappropriate model selection may yield false negatives.
• Solutions are stable only short-term; extended storage in solution reduces efficacy due to degradation.
• Dose must match published IC50 benchmarks; sub-nanomolar concentrations may be insufficient in some in vivo settings.

For detailed translational insights, see Liproxstatin-1: Potent Ferroptosis Inhibitor for Advanced Research, which explores workflow optimization—this article clarifies experimental limits and storage considerations.

Workflow Integration & Parameters

Liproxstatin-1 (APExBIO B4987) is provided as a lyophilized powder. For in vitro use, dissolve to ≥10.5 mg/mL in DMSO or ≥2.39 mg/mL in ethanol with gentle warming and ultrasound. Store at -20°C and prepare aliquots for single-use applications. Solutions should be used within days to maintain activity. In cellular assays, typical working concentrations range from 10–100 nM, depending on model and endpoint. For in vivo studies, dosing regimens must be titrated based on animal weight and model requirements. Always match control arms with vehicle (DMSO/ethanol) to exclude solvent effects. The B4987 kit includes a datasheet with detailed handling protocols (product page).

Conclusion & Outlook

Liproxstatin-1 is a benchmark ferroptosis inhibitor, enabling precise interrogation of the iron-dependent cell death and lipid peroxidation pathways. Its nanomolar potency, selectivity, and translational efficacy in organ injury models make it indispensable for mechanistic and preclinical research. As new forms of regulated cell death (e.g., cuproptosis) are elucidated (Yu et al., 2025), Liproxstatin-1 remains the gold standard for dissecting ferroptosis-specific events. For current product details and ordering, see the Liproxstatin-1 page at APExBIO.